India’s Fortis Healthcare is significantly expanding its dedicated obesity clinics India. This directly responds to the escalating demand for advanced weight-loss therapies across the nation. This strategic initiative emerges as popular weight-loss drugs like Eli Lilly’s Mounjaro and Novo Nordisk’s Wegovy gain considerable traction. These drugs increase patient awareness about effective weight management solutions.
The Indian healthcare landscape currently observes a sharp increase in patient interest and demand for structured guidance on weight management. This is particularly concerning newer obesity-related therapies. Mounjaro and Wegovy’s recent launch contributed significantly to this surge. Their sales doubled within months of introduction this year. Consequently, a robust market for obesity treatments is developing in India. Experts project India will have the world’s second-largest obese population by 2050.
Expanding Fortis Obesity Clinics Across Key Regions
Fortis Healthcare, a network comprising 28 hospitals and managed Gleneagles facilities, proactively addresses this growing healthcare need. The company has already established five obesity clinics India in major cities like Delhi, Gurgaon, Mumbai, and Bengaluru. Furthermore, Fortis plans to commission an additional 13 clinics within a year. These new facilities will span across key states. These include Punjab, Rajasthan, Karnataka, Maharashtra, West Bengal, and Haryana, ensuring broader access to specialized care.
Fortis plans to invest 7 billion rupees in hospital expansion over the next four years. This investment will scale up capacity in Bengaluru, Mumbai, the National Capital Region, and Punjab. It aligns with the company’s aim for high-teens percentage revenue growth.
Multidisciplinary Approach to Weight Management at India’s Obesity Clinics
The new obesity clinics India will offer comprehensive programs. These programs feature a multidisciplinary team of specialists. These teams include endocrinologists, experienced weight-loss surgeons, dedicated nutritionists, dieticians, and psychologists. Together, they will tailor personalized programs. This ensures holistic care based on individual patient requirements. This integrated healthcare model aims to deliver sustainable solutions for effective weight management. For those interested in deepening their understanding of endocrine disorders and their management, the Postgraduate Diploma In Endocrinology And Diabetes offers comprehensive training.
The Indian obesity drug market has seen remarkable growth. It expanded fivefold since 2021 to reach 6.28 billion rupees ($71.16 million). Competitive pricing and patients’ increased willingness to explore new treatment options primarily fuel this growth. Experts anticipate further market expansion when generic drugmakers introduce cheaper versions of Novo Nordisk’s offerings next year. Eli Lilly’s Mounjaro, for instance, recorded sales of ₹50 crore within three months of its March 2025 launch in India, demonstrating significant market acceptance.
Frequently Asked Questions
Q1: What is driving the expansion of obesity clinics in India?
A: Patient awareness and demand for advanced weight-loss therapies drive the expansion. New drugs like Eli Lilly’s Mounjaro and Novo Nordisk’s Wegovy have seen rapid sales growth.
Q2: What services will Fortis’s new obesity clinics offer?
A: Fortis’s obesity clinics will feature a multidisciplinary team. This team comprises endocrinologists, weight-loss surgeons, nutritionists, dieticians, and psychologists. They provide tailored, comprehensive weight management programs. Professionals looking to enhance their expertise in managing weight and associated metabolic issues may find the MSc In Obesity And Weight Management highly beneficial.
Q3: How much has the Indian anti-obesity drug market grown recently?
A: The Indian anti-obesity drug market grew fivefold since 2021, reaching 6.28 billion rupees ($71.16 million). Competitive pricing and patients’ readiness to try new medications fuel this growth.
References
- India’s Fortis to expand obesity clinics amid weight-loss therapy boom, CEO says – ETHealthworld
- Demand for obesity drugs shoots up in India as Lilly, Novo jostle for market share
- Fortis Healthcare Unveils Ambitious Expansion Plans, Targets 14-15% Revenue Growth
- Obesity drug demand soars in India: report – PRESS Insider
- India’s Anti-Obesity Drug Market Quadruples in 5 Years
- Fortis Hospital Vasant Kunj Launches Dedicated Obesity Clinic to Tackle India’s Growing Health Challenge – IHH Healthcare
- OBESITY CLINIC TEAM – Fortis Healthcare
- Fortis Hospital Vasant Kunj unveils obesity clinic in India | Healthcare Asia Magazine
- Can Mounjaro transform obesity care? ₹50 crore sales in three months – Business Standard
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.